EASD 2026, the 62nd annual meeting of the European Association for the Study of Diabetes, runs from September 28 to October 2, 2026 at the Allianz MiCo convention center in Milan.
Novo presented 44 abstracts, including OCTANE, a U.S. real-world study of people switching to the Wegovy pill. Lilly brought full Phase 3 TRIUMPH-2 results for retatrutide, published in The Lancet on September 30 (up to 20.8% weight loss at 80 weeks in adults with obesity and type 2 diabetes), and on October 1 showed in ACHIEVE-4 that its oral drug Foundayo was noninferior to insulin glargine on heart events. Boehringer's survodutide reached up to 13.1% weight loss in SYNCHRONIZE-2, with 18% stopping for gastrointestinal side effects.
The meeting closed on October 2 with the 2026 ADA-EASD type 2 diabetes consensus, which moves SGLT2 inhibitors and GLP-1-based therapies earlier in treatment. A Novo-funded Nordic registry study found no link between semaglutide and pancreatic cancer (hazard ratio 0.91), and Lilly's EloraTZP combination produced 23.3% weight loss at 48 weeks versus 14.8% for tirzepatide alone.
See #retatrutide, #cagrisema, and #amycretin.
The European Association for the Study of Diabetes (EASD) 62nd Annual Meeting takes place in Milan September 28 through October 2, 2026, and sets up the largest single September catalyst window for obesity-peptide investor and clinical interest. AstraZeneca will present Phase 2 data on AZD6234 (selective amylin receptor peptide agonist) monotherapy from APRICUS plus the ASCEND Phase 2b combination with AZD9550 GLP-1/glucagon dual agonist. Zealand Pharma and Roche will present petrelintide (amylin analog) data from ZUPREME-2 (obesity plus type 2 diabetes) with the Phase 3 monotherapy program preparing to initiate late 2026. Novo Nordisk will present amycretin (long-acting GLP-1/amylin dual agonist) plus CagriSema follow-through data. The EASD calendar coincides with the Roche Pharma Day investor event on Monday September 28, 2026 that will update on the top-three-obesity-portfolio (petrelintide, enicepatide, HM17321). Ascendis Pharma is also expected to provide TransCon CNP achondroplasia updates.
AstraZeneca's AZD6234 (a long-acting selective amylin receptor peptide agonist, weekly subcutaneous, currently in Phase 2 for obesity and type 2 diabetes) is queued for Phase 2 data presentations at the European Association for the Study of Diabetes (EASD) 62nd Annual Meeting in Milan September 28 to October 2, 2026. Trials on deck: APRICUS (obesity monotherapy) primary data 'imminent' per management; ARAY (NCT06851858, AZD6234 in obesity and type 2 diabetes on stable GLP-1 background); and the ASCEND Phase 2b (NCT06862791, 377 patients) that tests AZD6234 monotherapy, AZD9550 (AZ's GLP-1/glucagon dual agonist) monotherapy, and the combination against placebo over 36 weeks. Preliminary characterization suggests body-fat-selective weight loss and a generally tolerable profile. The readouts will provide a direct comparator against Novo Nordisk's CagriSema (semaglutide plus cagrilintide) and Metsera's MET-233i (monthly amylin) and set the near-term valuation frame for AZ's metabolic disease positioning after the $1.2 billion CSPC obesity licensing announced in January.